Abstracts tagged "inflammatory arthritis"

Abstract Number: 2056 • 2017 ACR/ARHP Annual Meeting
Performance and Validity of Musculoskeletal Ultrasound in the Assessment of Synovial Inflammation in Experimental Acute Gout
Raquel Largo¹, Juan Pablo Medina², Sandra Perez-Baos², Victor Najera-Aleson², Aranzazu Mediero², Gabriel Herrero-Beaumont¹ and Esperanza Naredo³, ¹Bone and Joint Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain, ²Joint and Bone Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain, ³Rheumatology, Joint and Bone Research Unit, IIS-FJD, Hospital Universitario Fundación Jiménez Díaz., Madrid, Spain
Background/Purpose: Musculoskeletal ultrasound (MS-US) has not been validated as a reliable technique to evaluate joint inflammation in an acute gout rabbit model. Rabbit has been…
Abstract Number: 107 • 2017 Pediatric Rheumatology Symposium
Children with Relapsing Polychondritis are likely to be seen in the emergency room prior to establishing the diagnosis
Marcela Ferrada¹, Ninet Sinaii², Keith A. Sikora³, Peter C. Grayson⁴, Thomas Christie⁵, Robert Colbert⁴ and James D. Katz⁶, ¹NIAMS, National Institues of Health, Bethesda, MD, ²Clinical Center, National Institutes of Health, Bethesda, MD, ³Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵Relapsing Polychondritis Awareness and Support Foundation, Anoka, MN, ⁶NIAMS, National Institutes of Health, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare immune-mediated disease characterized by recurrent episodes of chondritis. The pathogenesis of RP is poorly understood, and clinical manifestations…
Abstract Number: 2337 • 2016 ACR/ARHP Annual Meeting
Sleep Quality, Disturbances and Physical Activity: A Nationwide Survey Among Health Professionals on Their Engagement with Irish People Who Have Rheumatic Disease
Sean McKenna¹, Alan Donnelly², Sandy Fraser³ and Norelee Kennedy¹, ¹Department of Clinical Therapies, University of Limerick, Ireland, Limerick, Ireland, ²Department of Physical Education and Sports Sciences, University of Limerick, Ireland, Limerick, Ireland, ³Department of Rheumatology, University Hospitals Limerick, Ireland, Limerick, Ireland
Background/Purpose: Sleep disturbance is common in people who have inflammatory arthritis and can contribute to disability, symptomatology, and use of increased healthcare. Disturbed sleep is…
Abstract Number: 3251 • 2016 ACR/ARHP Annual Meeting
Sleep and Physical Activity: A Nationwide Survey Among People with Rheumatic Disease in Ireland
Sean McKenna¹, Alan Donnelly², Sandy Fraser³ and Norelee Kennedy¹, ¹Department of Clinical Therapies, University of Limerick, Ireland, Limerick, Ireland, ²Department of Physical Education and Sports Sciences, University of Limerick, Ireland, Limerick, Ireland, ³Department of Rheumatology, University Hospitals Limerick, Ireland, Limerick, Ireland
Background/Purpose: Sleep is an important aspect in maintaining the body’s circadian rhythm and plays an important role in maintaining health. Disrupted or lower levels…
Abstract Number: 19 • 2016 ACR/ARHP Annual Meeting
Tumour Necrosis Factor Inhibition Is Associated with Weight Gain in Patients with Inflammatory Arthritis
Peter Wong¹, Alison Bowling², Cheryl Tulk³, Di Freeman³ and Hanish Bagga³, ¹Mid-North Coast Arthritis Clinic and University of New South Wales Rural Clinical School, Coffs Harbour, Australia, ²School of Health and Human Sciences, Southern Cross University, Coffs Harbour, Australia, ³Mid-North Coast Arthritis Clinic, Coffs Harbour, Australia
Background/Purpose: Targeted blockade of tumour necrosis factor (TNF) has been a major therapeutic advance in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and…
Abstract Number: 25 • 2016 ACR/ARHP Annual Meeting
Have Outcomes of Patients with Inflammatory Arthritis Improved in the New Millennium? a Comparison of the 10 Year Outcome in Cohorts Recruited in 1990-4 and 2000-4
James Gwinnutt¹, Deborah P.M. Symmons^1,2, Alex J Macgregor^3,4, Jacqueline Chipping^3,4, Tarnya Marshall^3,4, Mark Lunt¹ and Suzanne M.M. Verstappen¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ³Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom, ⁴School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, United Kingdom
Background/Purpose: New treatments have improved the short term outlook for patients with inflammatory polyarthritis (IP) over the past 20 years. However there is limited evidence…
Abstract Number: 101 • 2016 ACR/ARHP Annual Meeting
Rheumatology Care Utilization and Geographic Distance from Rheumatology Sites within the United States Veteran Affairs Health Care System
Jessica A. Walsh¹, Zachary Burningham², Chia-Chen Teng, MS³, Daniel O. Clegg⁴ and Brian C. Sauer, PhD³, ¹University of Utah School of Medicine, Salt Lake City, UT, ²SLC Veterans Affairs Medical Center, SLC IDEAS Center, Salt Lake City, UT, ³Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁴Division of Rheumatology, University of Utah Medical Center, Salt Lake City, UT
Background/Purpose: Within the Veteran Affairs (VA) health care system, there are often large geographic distances between patients and rheumatology providers. The purpose of this study…
Abstract Number: 114 • 2016 ACR/ARHP Annual Meeting
The Effect of Triage Assessments on Identifying Inflammatory Arthritis and Reducing Rheumatology Wait Times in Ontario
Claire Bombardier¹, Sydney Brooks², Mary Bell³, Angela Cesta⁴, Tetyana Kendzerskaya⁵, Raquel Sweezie⁶, Jessica Widdifield⁷, Laura Fullerton⁸, Vandana Ahluwalia⁹ and Arthur Karasik¹⁰, ¹Toronto General Hospital Research Institute, Toronto, ON, Canada, ²The Arthritis Society, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Ontario Best Practices Research Initiative, University Health Network, Toronto, ON, Canada, ⁵Institute for Clinical Evaluative Studies, Toronto, ON, Canada, ⁶Arthritis Rehabilitation and Education Program, The Arthritis Society, Toronto, ON, Canada, ⁷McGill University, Montreal, QC, Canada, ⁸Division of Support, Systems and Outcomes, University Health Network, Toronto, ON, Canada, ⁹Ontario Rheumatology Association, Brampton, ON, Canada, ¹⁰Ontario Rheumatology Association, Toronto, ON, Canada
Background/Purpose: Excessive delays to rheumatologists have been documented and triage assessments of suspected IA referrals from primary care may be a key strategy to expedite…
Abstract Number: 298 • 2016 ACR/ARHP Annual Meeting
Disease Progression in Osteoarthritis Is Driven By Multiple Disease Parameters Leading to Comparable Levels of Joint Destruction
Anne C. Bay-Jensen¹, Asger Bihlet², Inger Byrjalsen², Jeppe Andersen³, Christian S. Thudium⁴, Bente J. Riis², Claus Christiansen², Hans Guehring⁵, Martin Michaelis⁵, Christoph Ladel⁵ and Morten Asser Karsdal⁶, ¹Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Nordic Bioscience, Clinical Development, Herlev, Denmark, ³Clinical Development, Nordic Bioscience, Herlev, Denmark, ⁴Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁵Merck KGaA, Darmstadt, Germany, ⁶Rheumatology, Nordic Bioscience, Herlev, Denmark
Background/Purpose: There is a need for successful drug development in osteoarthritis (OA) as there are currently no disease modifying drugs approved for OA. This may…
Abstract Number: 463 • 2016 ACR/ARHP Annual Meeting
Deficiency of Transmembrane Protein VISTA (V-domain Immunoglobulin Suppressor of T-cell Activation) Ameliorates Murine Collagen-II Antibody-Induced Arthritis
Roy Fava^1,2, Sabrina Ceeraz³, Susan Eszterhas⁴, Petra Sergent³, Christopher Burns⁵ and Mathew Vincenti^6,7, ¹Research, Department of Veterans Affairs, White River Junction, VT, ²Department of Medicinee, Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Microbiology/Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁴Research, Department of Veterans Affairs, white River Junction, VT, ⁵Section of Rheumatology, Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁶Department of Veterans Affairs, White River Junction, VT, ⁷Department of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: The transmembrane protein VISTA, is a member of the B7/CD28 family of immune modulator proteins and can function as a negative immune checkpoint regulator…
Abstract Number: 486 • 2016 ACR/ARHP Annual Meeting
IRF5 Promotes Arthritis but Restricts Virus Replication and Spread during Chikungunya Virus Infection
Jonathan Miner¹, Amber Smith², Raeann Shimak² and Michael Diamond³, ¹Internal Medicine / Rheumatology, Washington University in Saint Louis School of Medicine, Saint Louis, MO, ²Washington University in Saint Louis School of Medicine, Saint Louis, MO, ³Medicine / Infectious Diseases, Washington University in Saint Louis School of Medicine, Saint Louis, MO
Background/Purpose: Chikungunya virus (CHIKV) is an arthritogenic alphavirus that invades the joints and causes chronic arthritis in up to 60% of infected individuals. Over the…
Abstract Number: 726 • 2016 ACR/ARHP Annual Meeting
Comparison of Infliximab Immunogenicity in Inflammatory Arthritis Versus Inflammatory Bowel Disease Patients in Routine Clinical Practice
Marianne Guirgis¹, Melanie Favre dit Jeanfavre², Charles Benaim³, Matthieu Perreau⁴, Pierre Michetti⁵, Michel Maillard¹ and Pascal Zufferey⁶, ¹gastroenterology, Lausanne, Switzerland, ²DAL, RHU, Lausanne, Switzerland, ³DAL, MPR, Lausanne, Switzerland, ⁴Medecine /CHUV, Immunology, Lausanne, Switzerland, ⁵La Source-Beaulieu, Lausanne, Switzerland, ⁶Rhu /Dal .Chuv, Rheumatology, Lausanne, Switzerland
Background/Purpose: Infliximab is a biological agent frequently used for inflammatory arthritis (IA) such as spondyloarthritis, rheumatoid arthritis, psoriatic arthritis as well as for the inflammatory…
Abstract Number: 917 • 2016 ACR/ARHP Annual Meeting
B Cells Inhibit Osteoblast Differentiation in Inflammatory Arthritis
Wen Sun^1,2, Nida Meednu³, Alex Rosenberg¹, Javier Rangel-Moreno⁴, Victor Wang³, Teresa Owen¹, Hengwei Zhang⁵, Brendan Boyce¹, Jennifer H. Anolik¹ and Lianping Xing¹, ¹University of Rochester Medical Center, Rochester, NY, ²Nanjing Medical University, Nanjing, China, ³Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁴Allergy, Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is frequently associated with bone loss due to imbalanced bone resorption and formation. B cell depletion therapy (BCDT) attenuates bone erosion…
Abstract Number: 992 • 2016 ACR/ARHP Annual Meeting
The Impact of Inflammatory Arthritis (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, reactive arthritis) on Maternal and Neonatal Outcomes: A Population-Level Analysis
Stephanie Keeling¹, Anamaria Savu² and Padmaja Kaul³, ¹Department of Medicine, Division of Rheumatology, Edmonton, AB, Canada, ²Canadian Vigour Center, Edmonton, AB, Canada, ³Cardiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: The impact of inflammatory arthritis (IA) including rheumatoid (RA), psoriatic (PsA), and spondyloarthritis (SpA) on maternal, obstetrical and neonatal outcomes is not well described…
Abstract Number: 1033 • 2016 ACR/ARHP Annual Meeting
Targeting Notch-Activated M1 Macrophages Attenuates Joint Tissue Damage in a Mouse Model of Inflammatory Arthritis
Wen Sun^1,2, Hengwei Zhang³, Hua Wang^1,2, Yahui Grace Chiu⁴, Christopher T. Ritchlin⁵, Amy Kiernan¹, Brendan Boyce¹ and Lianping Xing¹, ¹University of Rochester Medical Center, Rochester, NY, ²Nanjing Medical University, Nanjing, China, ³Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, ⁴Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Increased expression of Notch signaling molecules has been reported in synovial samples of patients with rheumatoid arthritis (RA). However, the identity of the cell…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].